Clinical outcome measures of psoriasis

Reumatismo

Volumn 59, Issue SUPPL. 1, 2007, Pages 64-67

  Bonifati, C ^a   Berardesca, Enzo ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Outcome; Psoriasis; Psoriatic arthritis

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HOSPITALIZATION; HUMAN; ITALY; MEDICAL SOCIETY; METHODOLOGY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; HUMANS; ITALY; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL EXAMINATION; PROGNOSIS; PSORIASIS; QUALITY OF LIFE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 77953439468     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2007.1s.64     Document Type: Article

References (13)

1. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
2. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl II): ii65-8.
3. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Score (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-66.
4. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-9.
5. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003; 2: 260-6.
6. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
7. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998; 23: 391-8.
8. Felson D, Anderson J, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheuma toid arthritis. Arthritis Rheum 1995; 38: 727-35.
9. Fries J, Spitz P, Kraines R et al. Mea surement of patient outcomes in arthritis. Arthritis Rheum 1980; 23: 137-45.
10. Felson D, Anderson J, Lange M, Wells G, La Valley M. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improve ment in core set measures, rather then twenty percent? Arthritis Rheum 1998; 41: 1564-70.
11. Taylor WJ. Assessment of outcome in pso riatic arthritis. Curr Opin Rheumatol 2004; 16: 350-6.
12. Clegg D, Reda D, Mejias E et al. Com parison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a department of Veterans Affairs cooperative study. Arthri tis Rheum 1996; 39: 2013-20.
13. Gladman D, Helliwell P, Mease P, Nash P, Ritchling C, Taylor W. Asses ment of patients with psoriatic arthritis: a re view of currently available measures. Arthritis Rheum 2004; 50: 24-35.